Triglycerides and cardiovascular disease.

By Børge G. Nordestgaard, A. Varbo. The Lancet, 2014

1,388 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/8ca7c1a962ad8c80ba9e1e1525b04a6bde41a10e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. I. Graham
2. Jan Boren
3. Marja-Riitta Taskinen
4. J. Armitage
5. Børge G. Nordestgaard
6. S. Grundy
7. Ulrich Laufs

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. Jan Boren
3. S. Grundy
4. Marja-Riitta Taskinen
5. M. Chapman
6. Alberico L. Catapano
7. B. Lacey
8. J. Armitage

In Surgery

1. I. Graham
2. Jan Boren
3. M. Chapman
4. Marja-Riitta Taskinen
5. S. Grundy
6. Alberico L. Catapano
7. J. Armitage
8. Børge G. Nordestgaard

Citations in the corpus

• Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. (2016, result): “This finding is consistent with triglycerides being associated with vascular risk through the cholesterol content of remnant particles.(80) Recent genetic studies also support a causal role of triglyceride-mediated pathways in IHD.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “7 mmol/ L.(75) Severe HTG is rare and is typically associated with monogenic mutations.”
• Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (2016, neutral): “high risk of ASCVD and with all-cause mortality (Figure 3).(35) Indeed, for individuals in the general population with non-”
• Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020, background): “transcytosis, and are trapped prior to uptake as native (rather than modified) particles by macrophages to produce foam cells.(6,312) In”
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021, neutral): “3,25,80–92 4 ).”
• National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, background): “When triglycerides are between 200 and 499 mg/dL, the targets of therapy are non–HDL-C and LDL-C.”